SURF Profile
Surface Oncology Inc. (SURF) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, USA. The company is primarily focused on the development of novel immuno-oncology therapies designed to enhance anti-tumor immunity and target the tumor microenvironment.
The company's lead product candidate is SRF617, a fully human monoclonal antibody that targets CD39, an enzyme expressed on the surface of many immune cells and tumors that suppresses the immune response. SRF617 is currently being evaluated in a Phase 1 clinical trial for the treatment of advanced solid tumors. Surface Oncology is also developing a pipeline of other immuno-oncology therapies targeting various immune checkpoint pathways.
In September 2021, Surface Oncology announced a collaboration with Novartis to develop novel cancer immunotherapies. Under the terms of the agreement, Novartis will make an upfront payment of $40 million to Surface Oncology, and the two companies will work together to develop and commercialize SRF617 and other immuno-oncology product candidates.
In November 2021, Surface Oncology presented updated clinical data from its ongoing Phase 1 trial of SRF617 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. The data showed promising anti-tumor activity and a manageable safety profile.
As of September 30, 2021, Surface Oncology had $136.4 million in cash, cash equivalents, and marketable securities.
In August 2021, Surface Oncology announced a merger with Atlas Crest Investment Corporation, a special purpose acquisition company (SPAC). The merger is expected to close in the fourth quarter of 2021 or the first quarter of 2022, subject to regulatory and shareholder approvals.
|
